ERBB2 and breast carcinoma: We hypothesize that NAC with de-escalated taxane/trastuzumab regimens may be the preferred strategy for patients with T1/T2 N0 HER2+ breast cancer to minimize toxicity and identify patients with residual disease in need of escalated systemic therapy.